Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

Summary

The purpose of the study is to acquire additional data on efficacy, safety, tolerability, immunogenicity, pharmacokinetic (PK) and other parameters of HYQVIA in pediatric (age ≥ 2 to \<16 years) participants with primary immunodeficiency disease (PIDD).

Timeline

Start

2017-09-25

Primary completion

2022-07-20

Completion

2022-07-20

Publications

• Li Z, Teng Y, Russo-Schwarzbaum S, McCoy B. Pharmacokinetics of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in pediatric patients with primary immunodeficiency disease. Immunother Adv. 2026 Apr 3;6(1):ltag003. doi: 10.1093/immadv/ltag003. eCollection 2026.

Drugs

Indications